Anti-CGRP Migraine Antibodies: Clinical Trials vs Real-World Results
Review comparing anti-CGRP monoclonal antibody performance in clinical trials versus real-world evidence, showing real-world efficacy often matches or exceeds trial results with good safety profiles.
Quick Facts
What This Study Found
Real-world evidence for anti-CGRP monoclonal antibodies shows efficacy consistent with or exceeding clinical trial results, with maintained favorable safety profiles in routine clinical practice.
Key Numbers
Drugs: erenumab, fremanezumab, galcanezumab, eptinezumab; Phase III + real-world data; CGRP + PACAP pathways
How They Did This
Narrative review comparing randomized controlled trial data with real-world evidence studies for anti-CGRP monoclonal antibody migraine treatment.
Why This Research Matters
Real-world evidence confirms that the benefits of anti-CGRP drugs seen in carefully controlled trials translate to actual patient care — reassuring for both doctors and patients.
The Bigger Picture
The strong real-world performance of anti-CGRP drugs validates the CGRP hypothesis of migraine and supports expanded access to these treatments.
What This Study Doesn't Tell Us
Real-world studies have inherent biases (selection, recall, reporting). Comparison between trial and real-world data is indirect. Long-term real-world data still accumulating.
Questions This Raises
- ?Why might real-world efficacy exceed trial results?
- ?Are there specific patient populations that respond best in real-world settings?
- ?Does long-term real-world use reveal safety concerns not seen in trials?
Trust & Context
- Key Stat:
- Works in real life too Anti-CGRP antibodies perform at least as well in routine clinical practice as in controlled trials — the real-world evidence validates the clinical trial promise
- Evidence Grade:
- Moderate evidence: review comparing RCTs (high evidence) with real-world data (lower evidence but higher external validity).
- Study Age:
- Published 2021. Real-world anti-CGRP evidence continues to grow with expanding clinical use.
- Original Title:
- Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?
- Published In:
- Pharmaceuticals (Basel, Switzerland), 14(7) (2021)
- Authors:
- Mavridis, Theodoros, Deligianni, Christina I, Karagiorgis, Georgios, Daponte, Ariadne, Breza, Marianthi, Mitsikostas, Dimos D
- Database ID:
- RPEP-05590
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Do anti-CGRP drugs work as well in real life as in studies?
Yes — this review found that real-world effectiveness often matches or exceeds what was seen in clinical trials. This is reassuring because clinical trials have strict controls that don't represent normal patient care. The drugs genuinely help in everyday practice.
Are there any new safety concerns from real-world use?
The safety profile in real-world use has remained favorable and consistent with clinical trials. The most common side effects remain injection site reactions and constipation.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05590APA
Mavridis, Theodoros; Deligianni, Christina I; Karagiorgis, Georgios; Daponte, Ariadne; Breza, Marianthi; Mitsikostas, Dimos D. (2021). Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?. Pharmaceuticals (Basel, Switzerland), 14(7). https://doi.org/10.3390/ph14070700
MLA
Mavridis, Theodoros, et al. "Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?." Pharmaceuticals (Basel, 2021. https://doi.org/10.3390/ph14070700
RethinkPeptides
RethinkPeptides Research Database. "Monoclonal Antibodies Targeting CGRP: From Clinical Studies ..." RPEP-05590. Retrieved from https://rethinkpeptides.com/research/mavridis-2021-monoclonal-antibodies-targeting-cgrp
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.